T 0516/94 (Diltiazem formulations/ELAN) 01-04-1998

1. The appeal is admissible.

2. The late filing of the new set of claims 1 to 7 raises the procedural problem of their admissibility.

The Board notes that it is the normal purpose of oral proceedings to bring the case to a conclusion, Article 11(3) RPBA. The summons to oral proceedings are normally not sent before the basis for discussion is clearly apparent from the writs of the parties and/or, where appropriate, is defined in a communication from the Board. This implies that the requests have to be filed in advance. Thus, if an Appellant intends to file amendments it should do so in advance and not wait until the oral proceedings, which might jeopardize the usefulness of the oral proceedings.

Whether the Board of Appeal will consent to the subsequent filing of any amendments lies within its discretionary powers in accordance with Rules 66(1) and 86(3) EPC.

This means that for the decision as to whether the late-filed claims are admitted into the proceedings the Board of Appeal has to weigh the relevant criteria applicable to the case under consideration. Generally speaking the interest of the general public that proceedings before the EPO should be speedily concluded and unjustified procedural delays should be avoided, has to be balanced with the interest of the applicant, in particular in ex parte proceedings, where the application has been refused by the Examining Division, to defend his application as long as possible on as broad a basis as possible. In order to achieve this balance of interests the Boards of Appeal make the admission of late-filed requests dependent on factors such as the extent of lateness and the reasons given for the late filing, on the nature of the amendments made and on their allowableness, see the comprehensive report on case law on this issue in "Case law of the Boards of Appeal of the European Patent Office", 2nd edition, 1996, p.347 et seq.

2.1. Thus, according to established case law amended or entirely new requests are not permissible at this stage of the proceedings where there is considerable doubt as to whether the requirements under Article 123(2) EPC are met. This was the case with the sets of claims which the Appellant sought to introduce at the start of the oral proceedings.

On the contrary, it is to be noted that the last set of claims filed as the sole request as a consequence of the discussion during the oral proceedings a priori did not give rise to any problems regarding their support by the application documents originally filed. Claim 1 is based on claims 1, 2, 6, 7, originally filed and finds support on page 5, line 20 up to page 6 line 5 and page 8, lines 4 to 12 in combination with Example 1 on pages 21/22 and Example 3 on pages 23/24. Claim 2 is based on claim 3 originally filed. Claims 3 to 7 are based on claims 11 to 15 originally filed. The requirements of Article 123(2) EPC are accordingly satisfied.

2.2. Where the amendment, as is the case here, results from a combination of previous claims and/or only constitutes a restriction of the subject-matter to preferred embodiments of the invention it has to be regarded as being admissible (see i.a. T 252/92 point 3; T 626/90, point 2).

2.3. As regards the contents, i.e. the substance, of the sole main request filed in the oral proceedings the Board is of the opinion that the amendments constitute a bona fide attempt of the applicant to overcome the objections raised by the Examining Division in its decision to refuse the application for lack of inventive step (see e.g. T 38/89 and T 626/90: bona fide attempt accepted in inter partes proceedings).

Therefore, also considering the degree of success which might be achieved in a further examination procedure by the restriction of the claimed pellet formulation to a very special combination of polymer materials in the core and the membrane surrounding said core, the Board exercises its discretion under Rules 66(1) and 86(3) EPC in favour of the Appellant. Thus, it is decided to admit the new set of claims 1 to 7 into the proceedings.

3. The Board notes that the limitations in new claim 1 relating to polyvinylpyrrolidone as the polymeric material of the pellet core and EUDRAGIT RS and EUDRAGIT RL as the membrane- forming materials surrounding said core have not been really discussed during the proceedings before the Examining Division. The decision of the Examining Division is indeed focused on a discussion of peak plasma levels and the in-vitro pattern achievable when applying the teaching of document (1).

The Appellant has argued that having regard to the disclosure in document (1) the said limitations would show the claimed subject-matter in a more favourable light. However, it does not seem appropriate at the present stage of the proceedings for the Board to carry out an investigation in the state of the art on file on the basis of the new requests not having formed the basis for the decision of the Examining Division since the Appellant would be deprived of an instance of jurisdiction. Moreover, the essential function of appeal proceedings is seen to be to determine whether the decision of the first instance was correct (T 47/90, OJ EPO 1991, 486). Accordingly, in following the Appellant's request, the Board has decided to invoke its powers under Article 111(1) EPC and to remit the case to the Examining Division with the order to resume the examination on the newly-filed claims.

4. In the present case a complete examination, before dealing with the question of novelty and inventive step, should also make sure that the definition of the multi-layer membrane by the product names EUDRAGIT RS and EUDRAGIT RL under point "(ii)" of claim 1 is sufficient to define unambiguously the matter for which protection is sought and that a person skilled in the art confronted with the said product names and reading the application documents as a whole has no difficulty in carrying out the invention (see decision T 667/94 of 16. October 1997 of Board of Appeal 3.3.2, particularly point 4.4 of the reasons for the decision).